JOP20190107A1 - مثبطات أحادي أسيل جليسرول ليباز (magl) - Google Patents

مثبطات أحادي أسيل جليسرول ليباز (magl)

Info

Publication number
JOP20190107A1
JOP20190107A1 JOP/2019/0107A JOP20190107A JOP20190107A1 JO P20190107 A1 JOP20190107 A1 JO P20190107A1 JO P20190107 A JOP20190107 A JO P20190107A JO P20190107 A1 JOP20190107 A1 JO P20190107A1
Authority
JO
Jordan
Prior art keywords
magl
inhibitors
monoacylglycerol lipase
compositions
useful
Prior art date
Application number
JOP/2019/0107A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel J Buzard
Cheryl A Grice
Michael B Shaghafi
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62145825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20190107(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of JOP20190107A1 publication Critical patent/JOP20190107A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JOP/2019/0107A 2016-11-16 2017-06-16 مثبطات أحادي أسيل جليسرول ليباز (magl) JOP20190107A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423102P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
JOP20190107A1 true JOP20190107A1 (ar) 2019-05-09

Family

ID=62145825

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0107A JOP20190107A1 (ar) 2016-11-16 2017-06-16 مثبطات أحادي أسيل جليسرول ليباز (magl)

Country Status (27)

Country Link
US (2) US11059822B2 (2)
EP (1) EP3541820B1 (2)
JP (1) JP7042468B2 (2)
KR (1) KR20190080935A (2)
CN (1) CN110267962B (2)
AU (1) AU2017361253B2 (2)
BR (1) BR112019009880A2 (2)
CA (1) CA3043617A1 (2)
CL (1) CL2019001336A1 (2)
CO (1) CO2019004945A2 (2)
CR (1) CR20190239A (2)
DO (1) DOP2019000118A (2)
EA (1) EA038150B1 (2)
EC (1) ECSP19034535A (2)
ES (1) ES2952582T3 (2)
IL (1) IL266547B (2)
JO (1) JOP20190107A1 (2)
MA (1) MA46855A (2)
MX (1) MX389627B (2)
NI (1) NI201900049A (2)
PE (1) PE20191145A1 (2)
PH (1) PH12019501079A1 (2)
RU (1) RU2019115784A (2)
TN (1) TN2019000149A1 (2)
UA (1) UA125523C2 (2)
WO (1) WO2018093949A1 (2)
ZA (1) ZA201903099B (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
EA201992409A1 (ru) 2017-05-23 2020-03-23 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Ингибиторы magl на основе пиразола
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
AU2019304198A1 (en) * 2018-07-19 2021-02-04 Pfizer Inc. Heterocyclic spiro compounds as MAGL inhibitors
PE20211089A1 (es) 2018-08-13 2021-06-14 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
IL297470A (en) 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003002A (en) 1910-10-10 1911-09-12 Gustave J Martel Tire-patching device.
EP1368354A1 (en) 2001-03-07 2003-12-10 Pfizer Products Inc. Modulators of chemokine receptor activity
EP1948630A2 (en) 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CN102575076B (zh) 2009-09-29 2014-08-20 普立万公司 具有模拟金属或珠光外观的聚酯制品
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
CA2791672A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
CA2917050A1 (en) 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
CU24442B1 (es) 2014-04-04 2019-09-04 X Rx Inc Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
ES2878041T3 (es) * 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
US10519134B2 (en) 2015-11-20 2019-12-31 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EA036637B1 (ru) 2016-03-31 2020-12-02 Такеда Фармасьютикал Компани Лимитед Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP4335848A3 (en) 2017-03-13 2024-06-19 Lundbeck La Jolla Research Center, Inc. Dual magl and faah inhibitors
EA201992409A1 (ru) 2017-05-23 2020-03-23 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Ингибиторы magl на основе пиразола
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑

Also Published As

Publication number Publication date
PH12019501079A1 (en) 2019-08-19
ZA201903099B (en) 2021-01-27
CN110267962B (zh) 2022-04-01
EA201991029A1 (ru) 2019-12-30
AU2017361253B2 (en) 2021-08-05
US20200291023A1 (en) 2020-09-17
ECSP19034535A (es) 2019-05-31
IL266547A (en) 2019-07-31
KR20190080935A (ko) 2019-07-08
WO2018093949A1 (en) 2018-05-24
AU2017361253A1 (en) 2019-05-30
DOP2019000118A (es) 2019-09-30
UA125523C2 (uk) 2022-04-13
CA3043617A1 (en) 2018-05-24
EP3541820C0 (en) 2023-07-05
IL266547B (en) 2022-06-01
NI201900049A (es) 2019-10-30
PE20191145A1 (es) 2019-09-02
CL2019001336A1 (es) 2019-10-04
US11059822B2 (en) 2021-07-13
JP2020500178A (ja) 2020-01-09
ES2952582T3 (es) 2023-11-02
EP3541820A4 (en) 2020-06-10
CO2019004945A2 (es) 2019-05-21
RU2019115784A (ru) 2020-12-17
NZ753471A (en) 2021-01-29
US20220135563A1 (en) 2022-05-05
MX389627B (es) 2025-03-20
CN110267962A (zh) 2019-09-20
TN2019000149A1 (en) 2020-10-05
EP3541820A1 (en) 2019-09-25
EP3541820B1 (en) 2023-07-05
RU2019115784A3 (2) 2021-03-12
BR112019009880A2 (pt) 2019-08-13
EA038150B1 (ru) 2021-07-14
MX2019005773A (es) 2019-12-05
CR20190239A (es) 2019-06-26
JP7042468B2 (ja) 2022-03-28
MA46855A (fr) 2021-05-19
US11691975B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
JOP20190107A1 (ar) مثبطات أحادي أسيل جليسرول ليباز (magl)
PH12020551934A1 (en) Magl inhibitors
PH12019501097A1 (en) Magl inhibitors
PH12019501102A1 (en) Magl inhibitors
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MX2019014041A (es) Inhibidores pirazolicos de magl.
CR20190536A (es) Inhibidores pirazólicos de magl
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
EA201991898A1 (ru) Двойные ингибиторы magl и faah
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
JOP20200104B1 (ar) مركبات مثبطة لـ btk
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares